Status:

COMPLETED

Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus

Lead Sponsor:

Bayhill Therapeutics

Conditions:

Diabetes

Hypoglycemia

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to determine the safety of BHT-3021 injections given weekly for 12 weeks and to evaluate the effect of BHT-3021 on antibody and immune (T cell) responses to autoantigens (...

Detailed Description

Type 1 diabetes results from an attack by the body's own immune system on the insulin producing cells in the pancreas. Around 80% of diagnosed patients have detectable antibodies to islet cell self-pr...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Diagnosis of Type 1a Diabetes Mellitus based on ADA Criteria
  • ≤5 years since T1D was diagnosed
  • ≥ 18 years of age
  • ≤ 40 years of age at the time of diagnosis of Type 1a diabetes
  • Presence of antibodies to at least one of the following antigens:
  • insulin, GAD-65, or IA-2
  • Detectable fasting C-peptide level
  • C-peptide increase during screening mixed meal tolerance test with a minimal stimulated value of ≥ 0.2 pmol/mL
  • Presence of antibodies to at least one of the following antigens: insulin, GAD-65, or IA-2. If insulin antibody positive only, determination must be within 2 weeks of insulin initiation
  • Exclusion Criteria:
  • BMI \> 30 kg/m2
  • Unstable blood sugar control defined as one or more episodes of severe hypoglycemia (defined as hypoglycemia that required the assistance of another person) within the last 30 days
  • Current use of inhalable insulin
  • Previous immunotherapy for T1D
  • Administration of an experimental agent for T1D at any time or use of an experimental device for T1D within 30 days prior to screening, unless approved by the medical monitor
  • History of any organ transplant, including islet cell transplant

Exclusion

    Key Trial Info

    Start Date :

    October 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2011

    Estimated Enrollment :

    80 Patients enrolled

    Trial Details

    Trial ID

    NCT00453375

    Start Date

    October 1 2006

    End Date

    May 1 2011

    Last Update

    June 28 2011

    Active Locations (18)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (18 locations)

    1

    University of Alabama at Birmingham School of Medicine

    Birmingham, Alabama, United States, 35294

    2

    Valley Research

    Fresno, California, United States, 93720

    3

    Barbara Davis Center for Childhood Diabetes

    Aurora, Colorado, United States, 80045

    4

    Private Practice

    Denver, Colorado, United States, 80209